Integrated Diagnostics Holdings PLC (GB:IDHC)
LSE:IDHC
Want to see GB:IDHC full AI Analyst Report?
Top Page
Integrated Diagnostics Holdings
(LSE:IDHC)
Select Model
Select Model
Rating:69Neutral
Price Target:
$0.63
▲(0.48% Upside)
Action:N/A
Date:06/18/26
The score is driven primarily by solid financial performance (strong growth and healthy margins, with manageable leverage but rising absolute debt and less-consistent cash conversion). Valuation is supportive with a moderate P/E and modest yield, while technical signals are mixed/neutral with price below longer-term moving averages and slightly negative MACD.
Positive Factors
Revenue Momentum
Sustained +16.1% revenue growth in 2025 reflects durable demand expansion and improved market penetration. Over 2–6 months this supports better operating leverage, funding for organic investment and scale benefits that can sustainably raise competitive position and revenue visibility.
Negative Factors
Rising Absolute Debt
Absolute debt growth increases fixed obligations and refinancing exposure; if rates stay elevated or profitability weakens this can squeeze cash flow and restrict strategic flexibility. Over months this elevates interest cost risk and reduces capacity for opportunistic investments.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Momentum
Sustained +16.1% revenue growth in 2025 reflects durable demand expansion and improved market penetration. Over 2–6 months this supports better operating leverage, funding for organic investment and scale benefits that can sustainably raise competitive position and revenue visibility.
Read all positive factors
Integrated Diagnostics Holdings (IDHC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
$330.19M
Dividend Yield2.39%
Average Volume (3M)148.95K
Price to Earnings (P/E)12.7
Beta (1Y)1.01
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees6,309
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)1.88
Shares Outstanding581,326,300
10 Day Avg. Volume181,236
30 Day Avg. Volume148,946
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)6.10
Price to Sales (P/S)2.63
P/FCF Ratio14.92
Enterprise Value/Market Cap50.92
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit6.12
Enterprise Value/Ebitda8.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Integrated Diagnostics Holdings Business Overview & Revenue Model
Company Description
Integrated Diagnostics Holdings plc (IDHC.L) functions as a leading consumer healthcare enterprise, offering a wide array of medical diagnostic services directly to its clientele. The company's comprehensive service catalog features around 2,000 d...
Integrated Diagnostics Holdings Earnings Call Summary
Earnings Call Date:Apr 17, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 27, 2026
Earnings Call Sentiment Positive
The call presents a predominantly positive operating and financial performance: strong top-line growth (37%), substantial margin expansion (gross margin to 42.7%, EBITDA ~34%), improved working capital and liquidity, successful network expansion and strategic moves (radiotherapy acquisition, Saudi ramp, Nigeria turnaround). Key risks include regional geopolitical uncertainty, import/FX exposure (kits imported with inventory coverage only to August), concentrated revenue exposure to Egypt (84.6%), constrained Sudan operations, and a multi-year profitability timeline for Saudi. On balance, the positive operational momentum, margin improvement and liquidity position outweigh the risks highlighted.Positive Updates
Strong Revenue Growth
Group revenue grew 37% year-on-year in 2025, driven by both volume and value expansion across core markets.
Negative Updates
Geopolitical and Regional Uncertainty
Management flagged escalation of the U.S./Israel–Iran conflict (early 2026) as a source of heightened uncertainty that could negatively impact markets such as Jordan and Saudi Arabia and potentially affect patient volumes.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth
Group revenue grew 37% year-on-year in 2025, driven by both volume and value expansion across core markets.
Read all positive updates
Company Guidance
Management guided that for 2026 IDH expects revenue to grow ~25% (c.10% from price increases implemented in Jan‑2026 and c.15% from volume growth) while maintaining EBITDA margin around 33–34%; CapEx is budgeted at ~5.9% of sales (vs 4.8% in 2025) with most spend in Egypt, branch openings target ~200 across Egypt, Saudi and Jordan in 2026 (including six new Saudi branches to reach nine by year‑end), Biolab KSA revenue is targeted at SAR 18m with Saudi EBITDA expected to turn positive by 2028, inventory/test‑kit coverage is secured through August 2026 (all kits are imported), cash reserves stood at EGP 2.1bn (net cash EGP 472m, roughly USD 40m) as of Dec‑2025, the board declared a FY25 dividend of USD 0.0085/share (total USD 4.9m), and a share buyback is approved but not yet executed.Integrated Diagnostics Holdings Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.76B | 7.86B | 5.72B | 4.12B | 3.61B | 5.22B |
| Gross Profit | 2.75B | 3.35B | 2.18B | 1.52B | 1.46B | 2.80B |
| EBITDA | 2.01B | 2.89B | 2.09B | 1.28B | 1.29B | 2.57B |
| Net Income | 1.10B | 1.26B | 1.08B | 510.30M | 541.11M | 1.41B |
Balance Sheet | ||||||
| Total Assets | 7.50B | 8.60B | 7.13B | 5.77B | 5.30B | 6.24B |
| Cash, Cash Equivalents and Short-Term Investments | 1.74B | 2.13B | 1.75B | 860.51M | 815.92M | 2.35B |
| Total Debt | 1.36B | 1.61B | 1.47B | 1.18B | 1.18B | 858.74M |
| Total Liabilities | 3.67B | 4.46B | 3.63B | 2.67B | 2.85B | 3.44B |
| Stockholders Equity | 3.12B | 3.38B | 2.71B | 2.68B | 2.15B | 2.58B |
Cash Flow | ||||||
| Free Cash Flow | 1.26B | 1.38B | 1.34B | 217.73M | -100.11M | 2.01B |
| Operating Cash Flow | 1.51B | 1.90B | 1.57B | 543.66M | 208.73M | 2.27B |
| Investing Cash Flow | -111.42M | -552.92M | -446.71M | -243.94M | 990.11M | -1.33B |
| Financing Cash Flow | -893.28M | -851.06M | -749.00M | -330.46M | -1.62B | -647.15M |
Integrated Diagnostics Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £91.17M | 12.82 | 65.83% | 8.33% | -8.21% | -5.27% | |
69 Neutral | $330.19M | 12.68 | 42.26% | 2.39% | ― | ― | |
59 Neutral | £111.46M | 56.62 | 3.01% | ― | 2.73% | -65.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £4.16M | 3.05 | 12.15% | ― | -10.20% | 714.29% | |
50 Neutral | £28.43M | -14.01 | -55.91% | ― | 40.37% | -13.70% | |
49 Neutral | £20.87M | -2.06 | -153.92% | ― | 65.60% | 74.84% |
* Healthcare Sector Average
GB:IDHC
Integrated Diagnostics Holdings
0.57
0.23
70.57%
GB:BVXP
Bioventix
1,745.00
-759.68
-30.33%
GB:EKF
EKF Diagnostics Holdings
25.90
-0.55
-2.08%
GB:GDR
Genedrive
1.30
-0.16
-10.78%
GB:CNSL
Omega Diagnostics
1.75
-1.70
-49.28%
GB:ABDX
Abingdon Health PLC
11.25
4.50
66.67%
Integrated Diagnostics Holdings Corporate Events
Business Operations and StrategyFinancial Disclosures
Integrated Diagnostics lifts Q1 revenue 31% as branch expansion drives test volumes
Positive
May 20, 2026
Integrated Diagnostics Holdings reported strong first-quarter 2026 results, with revenue rising 31% year on year to EGP 2.1 billion, driven by a 22% increase in test volumes and higher revenue per test. The group expanded its network to 794 branch...
Business Operations and StrategyFinancial Disclosures
Integrated Diagnostics lifts Q1 revenue 31% on regional volume growth
Positive
May 20, 2026
Integrated Diagnostics Holdings posted a 31% year-on-year rise in first-quarter 2026 revenue to EGP 2.1 billion, driven by a 22% increase in test volumes and higher pricing and service mix, particularly in Egypt. The group’s expanding 794-br...
Business Operations and StrategyExecutive/Board ChangesStock BuybackDividendsFinancial DisclosuresShareholder Meetings
Integrated Diagnostics Wins Strong Shareholder Backing at 2026 AGM
Positive
May 19, 2026
Integrated Diagnostics Holdings reported that all resolutions at its 19 May 2026 annual general meeting were approved by shareholders, including the re-election of several directors and the reappointment of PwC as auditor. The meeting also endorse...
Financial DisclosuresRegulatory Filings and ComplianceShareholder Meetings
Integrated Diagnostics Publishes 2025 Annual Report and Sets 2026 AGM Date
Positive
Apr 23, 2026
Integrated Diagnostics Holdings has published its 2025 Annual Report and Accounts on its investor website and has mailed the report, the notice of its 2026 Annual General Meeting, and a letter of availability to shareholders. The AGM will be held ...
Business Operations and StrategyDividendsFinancial DisclosuresM&A Transactions
Integrated Diagnostics posts 37% revenue surge and margin gains on network expansion
Positive
Apr 17, 2026
Integrated Diagnostics Holdings reported strong financial and operational performance for 2025, with revenues climbing 37% to EGP 7.9 billion on the back of an 11% increase in test volumes and a 24% rise in average revenue per test. The group expa...
Business Operations and StrategyDividendsFinancial Disclosures
Integrated Diagnostics boosts 2025 profits on strong growth and margin gains
Positive
Apr 17, 2026
Integrated Diagnostics Holdings reported strong full-year 2025 results, with revenue rising 37% to EGP 7.9 billion, driven by an 11% increase in test volumes and a 24% rise in average revenue per test. Profitability improved sharply as gross margi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.